

In the Specification

In col. 1 of the specification, please amend the paragraph found on lines 4-7 to read as follows:

This application is a reissue of application 09/517,751, which was filed on March 3, 2000 and which issued as U.S. 6,479,551 on November 12, 2002. The '751 application was a continuation-in-part of U.S. Ser. No. 08/966,506, filed Nov. 10, 1997 (now U.S. Pat. No. 6,077,539), which is a continuation-in-part of U.S. application Ser. No. 08/748,332, filed Nov. 12, 1996, now abandoned.

Please amend the paragraph beginning in col. 1, line 61 and continuing through col. 2, line 5, to read as follows:

Metoclopramide is a drug known to relieve migraine-associated nausea when administered at a minimum oral dose of 10 mg. Poyser et al. have described a formulation in which analgesics such as aspirin, paracetamol or paracetamol DC [is] are uniformly intermixed with metoclopramide (U.S. Pat. No. 4,380,540). One drawback of [this formulation] formulations containing aspirin is that, [it undergoes] as discussed further herein, they should undergo unacceptable degradation in a matter of two to three weeks at ambient temperatures. In addition, aspirin is known to have a very short plasma half life. New formulations of metoclopramide that are effective in treating migraine headache and that avoid the disadvantages of this and other previously disclosed preparations would represent a clear advance in the art.